MedPeerInc Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

MedPeerInc wird ein jährliches Gewinn- und Umsatzwachstum von 4.5% bzw. 3.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.7% betragen.

Wichtige Informationen

4.5%

Wachstumsrate der Gewinne

4.5%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	17.0%
Wachstumsrate der Einnahmen	3.8%
Zukünftige Eigenkapitalrendite	8.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

Nov 15

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Sep 04

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

Aug 02

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

May 21

Gewinn- und Umsatzwachstumsprognosen

TSE:6095 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2027	17,177	930	659	N/A	4
9/30/2026	16,120	842	649	N/A	4
9/30/2025	15,092	745	560	N/A	4
9/30/2024	15,368	1,359	541	N/A	4
6/30/2024	15,303	638	N/A	N/A	N/A
3/31/2024	15,261	436	1,160	1,284	N/A
12/31/2023	15,006	636	N/A	N/A	N/A
9/30/2023	14,540	617	495	600	N/A
6/30/2023	12,691	566	N/A	N/A	N/A
3/31/2023	11,141	594	323	438	N/A
12/31/2022	9,787	712	N/A	N/A	N/A
9/30/2022	8,452	812	691	853	N/A
6/30/2022	8,375	1,004	N/A	N/A	N/A
3/31/2022	8,071	1,121	1,014	1,238	N/A
12/31/2021	7,848	1,226	N/A	N/A	N/A
9/30/2021	7,435	1,293	1,114	1,361	N/A
6/30/2021	7,155	1,183	N/A	N/A	N/A
3/31/2021	6,804	1,154	967	1,170	N/A
12/31/2020	6,308	1,011	N/A	N/A	N/A
9/30/2020	5,311	725	759	930	N/A
6/30/2020	4,457	626	N/A	N/A	N/A
3/31/2020	3,811	510	480	617	N/A
12/31/2019	3,224	418	N/A	N/A	N/A
9/30/2019	3,045	394	262	374	N/A
6/30/2019	2,842	292	N/A	N/A	N/A
3/31/2019	2,672	330	346	437	N/A
12/31/2018	2,414	283	N/A	N/A	N/A
9/30/2018	2,199	206	260	344	N/A
6/30/2018	2,090	-165	N/A	N/A	N/A
3/31/2018	1,921	-262	N/A	189	N/A
12/31/2017	1,745	-327	N/A	N/A	N/A
9/30/2017	1,559	-371	N/A	179	N/A
9/30/2016	973	23	N/A	4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 6095Das prognostizierte Gewinnwachstum (4.5% pro Jahr) liegt über der Sparquote (0.3%).

Ertrag vs. Markt: 6095Die Erträge des Unternehmens (4.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (8% pro Jahr).

Hohe Wachstumserträge: 6095Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 6095Die Einnahmen des Unternehmens (3.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (4.2% pro Jahr).

Hohe Wachstumseinnahmen: 6095Die Einnahmen des Unternehmens (3.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 6095Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.7%).

MedPeerInc Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 31%

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 19%, revenue upgraded

Price target decreased by 9.1% to JP¥1,250

Recent updates

These 4 Measures Indicate That MedPeerInc (TSE:6095) Is Using Debt Safely

MedPeer,Inc., Annual General Meeting, Dec 18, 2024

New minor risk - Share price stability

Upcoming dividend of JP¥4.50 per share

Consensus EPS estimates increase by 31%

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Now 21% overvalued after recent price rise

MedPeer,Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Third quarter 2024 earnings released: EPS: JP¥10.59 (vs JP¥1.28 in 3Q 2023)

Investor sentiment deteriorates as stock falls 27%

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

MedPeer,Inc. to Report Q3, 2024 Results on Aug 14, 2024

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

Second quarter 2024 earnings released: JP¥4.15 loss per share (vs JP¥5.02 profit in 2Q 2023)

New minor risk - Market cap size

MedPeer,Inc. to Report Q2, 2024 Results on May 13, 2024

Consensus EPS estimates fall by 19%, revenue upgraded

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released: EPS: JP¥13.33 (vs JP¥12.40 in 1Q 2023)

New minor risk - Market cap size

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Q1, 2024 Results on Feb 13, 2024

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 9.1% to JP¥1,250

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Now 27% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Third quarter 2023 earnings released: EPS: JP¥1.28 (vs JP¥2.59 in 3Q 2022)

MedPeer,Inc. to Report Q3, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥5.02 (vs JP¥10.56 in 2Q 2022)

MedPeer,Inc. (TSE:6095) announces an Equity Buyback for 300,000 shares, representing 1.37% for ¥300 million.

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: EPS: JP¥12.40 (vs JP¥17.15 in 1Q 2022)

MedPeer,Inc. (TSE:6095) acquired Business support application series of recruit Medical Career.

Price target decreased to JP¥2,300

MedPeer,Inc. to Report Q1, 2023 Results on Feb 13, 2023

Now 20% undervalued

Now 23% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 19%

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

Price target decreased to JP¥2,600

MedPeer,Inc. (TSE:6095) completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.

MedPeer,Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 31%

Third quarter 2022 earnings released: EPS: JP¥2.59 (vs JP¥8.03 in 3Q 2021)

MedPeer,Inc. (TSE:6095) entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for ¥5000 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to JP¥3,580

Investor sentiment deteriorated over the past week

MedPeer,Inc. to Report Q3, 2022 Results on Aug 09, 2022

Price target decreased to JP¥4,276

MedPeer,Inc. (TSE:6095) acquired Minkore recently.

Price target decreased to JP¥4,496

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No independent directors

MedPeer,Inc. to Report Q2, 2022 Results on May 12, 2022